Biomarkers are absolutely the key to choosing the right drug for the right patient! Amazing breakdown of how we use them in clinical trials, by Dr. Katherine Fuh @Fuh_Lab SGO #SGOMtg

Especially proud today to be colleagues with BJ Rimel as she presented GY012! We need more platform trials like this to allow efficient evaluation of various treatments in our patient populations at greatest need! #SGOMtg SGO @CSCancerCare OB/GYN at Cedars-Sinai

Kudos to @michaelrmanuel!

Thank you to tennis legend Chris Evert for sharing her ovarian cancer diagnosis to raise awareness! Know your family history and talk to your doctor about symptoms. Chris Evert UCLA Obstetrics and Gynecology IGCS SGO

We’re pleased to share that our very own faculty, Dr. BJ Rimel, has been appointed as the medical director for the Cancer Trials Office (CCTO)! Please join us in congratulating Dr. Rimel on this outstanding accomplishment. BJ Rimel @CSCancerCare

Amazing opportunity for such an at-need population, from the great Katherine Fuh!

Sharing an uplifting story on the power of trust and gratitude, featuring a patient who’s like family to me!

Our own Kristin Taylor MD spoke at The Women’s Connection Disney Disney+ Disney Branded TV PR for #InternationalWomensDay2023! (📸: Kenneth H Kim)

A great annual review and thoughtful discussion of key ongoing trials in the world of Gyn Oncology!

This is a great report- now we need a trial in LGSOC so we can know if being FR alpha + = efficacy?

September is #GynecologicCancerAwarenessMonth, which includes cervical, ovarian, uterine/endometrial, vaginal, & vulvar cancer. According to National Cancer Institute, more than 108,000 women in the US are expected to be diagnosed in 2024. AACR ow.ly/ymt650TaNCC

For the inaugural #LGSOCAwarenessDay, Amanda is sharing her story of coping with recurrence. 80% of people treated for LGSOC will have their cancer come back. #LGSOC #VerastemOnc

A great critique by Dr. Moore! We’ve shown ourselves that in unselected patients, the addition of immunotherapy does not make much of a difference. But is there a biomarker-selected group that may benefit?

I’m grateful to join the SHE MD podcast alongside Taylor Odlozil to discuss his late wife Haley’s courageous journey through stage 3C ovarian cancer. youtu.be/2jxLCTGpL_8?si…

Clear question, clear answer - great opening to the SGO annual meeting!

This window of opportunity trial demonstrated an 80% complete response rate to neoadjuvant ICI in resectable dMMR endometrial cancer! Could this be an emerging option for fertility-sparing or medically frail patients? #SGO2025

❓What are the barriers to #clinicaltrial enrollment? 🤩Bottom line- patients want to hear about trials from their providers! We can’t assume patients are not interested. 💡Standard approaches to recruitment are needed!! #SGOMtg #SGO2025 #gyncsm

Cyclin E1 by IHC > gene amplification as a biomarker for response to Wee1 inhibitor, with ORR 35%! So exciting to see this move to the next stage with only biomarker selected patients!

Incredible work targeting MAPK-driven mesonephric/mesonephric-like Gyn cancer with dual RAF/MEKi + FAKi to block an “adaptive resistance” mechanism - a powerhouse combo by Verastem Oncology

Thrilled at the FDA accelerated approval of this brilliantly designed and well-tolerated oral regimen for patients with low-grade serous ovarian cancer!!!